Immunomodulation of thalidomide is represented by the antiinflammatory effect through inhibition of tumor necrosis factor (alpha) and costimulatory effect on human CD8+ T cells. We investigated the efficacy and safety of a 24-wk course of thalidomide at a dosage of 200 mg/day in eight patients with HCV chronic hepatitis nonresponders to interferon (alpha) plus ribavirin. We observed a significant mean decrease of serum aminotransferases and (gamma)-glutamyltransferases of 39% and 61%, respectively (p= 0.017 and 0.02). Tumor necrosis factor-(alpha)in vitro production in mononuclear cells decreased with thalidomide in all the subjects (p= 0.028). Perforin- and granzyme-specific mRNA expression increased under thalidomide without statistical significance. A positive correlation between biochemical and immunological parameters was observed with higher increase of granzyme and perforin values in patients showing reduction of aminotransferases. Finally upregulation of T-helper 1 cytokine expression as mean interferon (gamma)/IL-10 ratio was evidenced. Thalidomide was well tolerated. In conclusion, thalidomide was able to reduce liver enzymes in six out of eight patients with chronic hepatitis C and to reduce tumor necrosis factor (alpha) production, representing a promising new approach for the treatment of HCV infection. (copyright) 2006 by Am. Coll. of Gastroenterology Published by Blackwell Publishing.

Thalidomide in the treatment of chronic hepatitis C unresponsive to alfa-interferon and ribavirin / L. Milazzo, M. Biasin, N. Gatti, L. Piacentini, F. Niero, B. Zanone Poma, M. Galli, M. Moroni, M. Clerici, A. Riva. - In: THE AMERICAN JOURNAL OF GASTROENTEROLOGY. - ISSN 0002-9270. - 101:2(2006), pp. 399-402. [10.1111/j.1572-0241.2006.00350.x]

Thalidomide in the treatment of chronic hepatitis C unresponsive to alfa-interferon and ribavirin

M. Biasin
Secondo
;
N. Gatti;L. Piacentini;B. Zanone Poma;M. Galli;M. Moroni;M. Clerici
Penultimo
;
A. Riva
2006

Abstract

Immunomodulation of thalidomide is represented by the antiinflammatory effect through inhibition of tumor necrosis factor (alpha) and costimulatory effect on human CD8+ T cells. We investigated the efficacy and safety of a 24-wk course of thalidomide at a dosage of 200 mg/day in eight patients with HCV chronic hepatitis nonresponders to interferon (alpha) plus ribavirin. We observed a significant mean decrease of serum aminotransferases and (gamma)-glutamyltransferases of 39% and 61%, respectively (p= 0.017 and 0.02). Tumor necrosis factor-(alpha)in vitro production in mononuclear cells decreased with thalidomide in all the subjects (p= 0.028). Perforin- and granzyme-specific mRNA expression increased under thalidomide without statistical significance. A positive correlation between biochemical and immunological parameters was observed with higher increase of granzyme and perforin values in patients showing reduction of aminotransferases. Finally upregulation of T-helper 1 cytokine expression as mean interferon (gamma)/IL-10 ratio was evidenced. Thalidomide was well tolerated. In conclusion, thalidomide was able to reduce liver enzymes in six out of eight patients with chronic hepatitis C and to reduce tumor necrosis factor (alpha) production, representing a promising new approach for the treatment of HCV infection. (copyright) 2006 by Am. Coll. of Gastroenterology Published by Blackwell Publishing.
Settore MED/17 - Malattie Infettive
Settore MED/04 - Patologia Generale
Settore BIO/13 - Biologia Applicata
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/21989
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 10
social impact